Weight loss with atogepant in the long‐term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open‐label, 156‐week extension study

Dale S. Bond, Jonathan H. Smith, Alexandra Sinclair, Peter J. Goadsby, Jessica Ailani, Yingyi Liu, Rosa De Abreu Ferreira, Brett Dabruzzo, Joel M. Trugman, B. Lee Peterlin

Open source

DOI
10.1111/head.70162
Published
2026-07-03
Container
Headache: The Journal of Head and Face Pain
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/head.70162,
  title = {Weight loss with atogepant in the long‐term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open‐label, 156‐week extension study},
  author = {Dale S. Bond and Jonathan H. Smith and Alexandra Sinclair and Peter J. Goadsby and Jessica Ailani and Yingyi Liu and Rosa De Abreu Ferreira and Brett Dabruzzo and Joel M. Trugman and B. Lee Peterlin},
  year = {2026},
  journal = {Headache: The Journal of Head and Face Pain},
  doi = {10.1111/head.70162},
  url = {https://doi.org/10.1111/head.70162}
}

RIS

TY  - JOUR
TI  - Weight loss with atogepant in the long‐term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open‐label, 156‐week extension study
AU  - Dale S. Bond
AU  - Jonathan H. Smith
AU  - Alexandra Sinclair
AU  - Peter J. Goadsby
AU  - Jessica Ailani
AU  - Yingyi Liu
AU  - Rosa De Abreu Ferreira
AU  - Brett Dabruzzo
AU  - Joel M. Trugman
AU  - B. Lee Peterlin
PY  - 2026
JO  - Headache: The Journal of Head and Face Pain
DO  - 10.1111/head.70162
UR  - https://doi.org/10.1111/head.70162
ER  - 

APA

Bond, D. S., Smith, J. H., Sinclair, A., Goadsby, P. J., Ailani, J., Liu, Y., Ferreira, R. D. A., Dabruzzo, B., Trugman, J. M., & Peterlin, B. L. (2026). Weight loss with atogepant in the long‐term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open‐label, 156‐week extension study. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.70162

Source records